Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. The epidemic of diabetes mellitus is expected to result in one of the steepest rises in human morbidity and mortality ever observed outside of wartime. Insulin resistance is a hallmark of pre-diabetes and type 2 diabetes mellitus, and is characterized by impaired insulin-signaling transduction. Authoritative and comprehensive,Lipoproteins in Diabetes Mellitus details the many changes wrought by insulin resistance and diabetes mellitus on lipid and lipoprotein metabolism. The book begins by summarizing the various techniques to measure lipoproteins and their subclasses. The mechanisms by which insulin resistance and diabetes mellitus increase risk for atherosclerosis, diabetic retinopathy, and diabetic nephropathy are then explored in detail. Finally, the effects of lifestyle modification and the results of clinical trials using established and investigational drugs are discussed.
An invaluable contribution to the literature, Lipoproteins in Diabetes Mellitusis a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It will have a long-lasting and significant effect on the medical management of people with diabetes.
Here is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It features recent major diabetes and lipid related clinical trials, and includes tables and figures to highlight major points.
Arvustused
From the book reviews: "This volume reviews in 23 chapters the lipid and lipoprotein changes induced by diabetes mellitus. It contains didactic color illustrations and many references. For clinical and research diabetologists, pharmacologists and biochemists." (Pediatric Endocrinology Reviews (PER), Vol. 12 (1), September, 2014)
|
1 Laboratory Assessment of Lipoproteins in Diabetes |
|
|
1 | (10) |
|
|
|
|
|
2 Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes |
|
|
11 | (30) |
|
|
|
|
|
|
|
3 Insulin Resistance and Atherosclerosis |
|
|
41 | (14) |
|
|
|
|
|
4 Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes |
|
|
55 | (46) |
|
|
|
5 Lipoprotein Metabolism and Alterations Induced by Insulin Resistance and Diabetes |
|
|
101 | (24) |
|
|
|
|
|
6 Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States |
|
|
125 | (16) |
|
|
|
|
|
|
|
7 Lipoprotein(a): Structure, Metabolism, and Pathophysiology |
|
|
141 | (16) |
|
|
|
|
|
|
|
8 Lipoprotein Glycation in Diabetes Mellitus |
|
|
157 | (30) |
|
|
|
|
|
|
|
9 Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus |
|
|
187 | (16) |
|
|
|
|
|
|
|
10 The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes |
|
|
203 | (12) |
|
|
|
|
|
11 Lipid: Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes |
|
|
215 | (16) |
|
|
|
|
|
12 Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus |
|
|
231 | (8) |
|
|
|
13 Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy |
|
|
239 | (40) |
|
|
|
|
|
14 Lipoproteins and Diabetic Nephropathy |
|
|
279 | (22) |
|
|
|
|
|
|
|
15 Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy |
|
|
301 | (14) |
|
|
|
|
|
16 Effects of Lifestyle (Diet, Plant Sterols, Exercise) and Glycemic Control on Lipoproteins in Diabetes |
|
|
315 | (14) |
|
|
|
17 About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus |
|
|
329 | (18) |
|
|
|
|
|
|
|
18 Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients |
|
|
347 | (10) |
|
|
|
|
|
|
|
19 The PPAR System in Diabetes |
|
|
357 | (16) |
|
|
|
|
|
20 Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients |
|
|
373 | (26) |
|
|
|
21 Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients |
|
|
399 | (16) |
|
|
|
|
|
|
|
22 Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus |
|
|
415 | (20) |
|
|
|
23 Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes |
|
|
435 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
| Index |
|
455 | |
Alicia Jenkins, MBBS, MD, FRACP, FRCP University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Oklahoma City, OK, USA
Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC CGH Medical Center, Sterling, IL University of Illinois College of Medicine, Clinical Family and Community Medicine, Peoria, IL Michigan State University College of Osteopathic Medicine, Clinical Medicine, East Lansing, MI, USA
Timothy J. Lyons, MD, FRCP University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Harold Hamm Diabetes Center, Oklahoma City, OK, USA
